URIC ACID PROTECTION FROM MPTP NEUROTOXICITY

尿酸防止 MPTP 神经毒性

基本信息

  • 批准号:
    2624917
  • 负责人:
  • 金额:
    $ 9.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-05-01 至 2002-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: The cause of selective dopamine neuron loss associated with Parkinson's disease (PD) is unknown. There has been growing interest in understanding the role of endogenous antioxidants in controlling oxidative stress, as well as being potential therapeutic agents in slowing the progression of PD. The long-term objective of this application is to generate experimental evidence on the role of uric acid as an endogenous antioxidant. This proposal describes experiments designed to determine if uric acid functions as a neuroprotector by investigating whether increasing or decreasing endogenous uric acid levels has an effect on the destruction of dopamine cells. This will be achieved by treating guinea pigs with purine enzyme inhibitors concomitantly with the dopamine neurotoxin MPTP. The specific aim of this proposal is to determine if changes in uric acid levels in the nigrostriatal system can influence the degree of dopamine cell death in the guinea pigs following MPTP treatment.
选择性多巴胺神经元丢失的原因与

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM H CHURCH其他文献

WILLIAM H CHURCH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM H CHURCH', 18)}}的其他基金

SINGLE CRYSTAL X-RAY DIFFRACTION OF INHIBITED PHOSPHOLIPASE AND KYNURENINE AM
受抑制的磷脂酶和犬尿氨酸 AM 的单晶 X 射线衍射
  • 批准号:
    7601608
  • 财政年份:
    2007
  • 资助金额:
    $ 9.71万
  • 项目类别:
SINGLE CRYSTAL X-RAY DATA COLLECTION FOR PHOSPHOLIPASE AND INHIBITORS
磷脂酶和抑制剂的单晶 X 射线数据收集
  • 批准号:
    7601592
  • 财政年份:
    2007
  • 资助金额:
    $ 9.71万
  • 项目类别:
INHIBITION AND MECHANISM STUDIES OF SECRETED PHOSPHOLIPASE A2, KYNURENINE AMI
分泌型磷脂酶A2、犬尿氨酸AMI的抑制及机制研究
  • 批准号:
    7601574
  • 财政年份:
    2007
  • 资助金额:
    $ 9.71万
  • 项目类别:
AMINERGIC & NPY REGULATION OF THE REPRODUCTIVE AXIS
胺能
  • 批准号:
    3036734
  • 财政年份:
    1988
  • 资助金额:
    $ 9.71万
  • 项目类别:

相似国自然基金

Apocynin和allopurinol对运动上调自发性高血压大鼠肾脏一氧化氮合成酶表达的影响
  • 批准号:
    81301667
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Allopurinol Improves Diastolic Function in African Americans with Resistant Hypertension
别嘌呤醇可改善患有难治性高血压的非裔美国人的舒张功能
  • 批准号:
    10701217
  • 财政年份:
    2023
  • 资助金额:
    $ 9.71万
  • 项目类别:
Association Between Allopurinol and Cardiovascular Events, Mortality and End-Stage Renal Disease in Diabetes
别嘌呤醇与糖尿病心血管事件、死亡率和终末期肾病之间的关联
  • 批准号:
    377029
  • 财政年份:
    2017
  • 资助金额:
    $ 9.71万
  • 项目类别:
    Fellowship Programs
CKD-FIX: a randomised, controlled trial of allopurinol in the slowing of kidney disease progression
CKD-FIX:别嘌呤醇减缓肾脏疾病进展的随机对照试验
  • 批准号:
    nhmrc : GNT1043203
  • 财政年份:
    2013
  • 资助金额:
    $ 9.71万
  • 项目类别:
    Project Grants
PERL: A multi-center clinical trial of allopurinol to prevent GFR loss in T1D
PERL:别嘌呤醇预防 T1D 患者 GFR 损失的多中心临床试验
  • 批准号:
    9738022
  • 财政年份:
    2013
  • 资助金额:
    $ 9.71万
  • 项目类别:
PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1D
PERL:别嘌呤醇预防 T1D 患者 GFR 损失的多中心临床试验
  • 批准号:
    8644403
  • 财政年份:
    2013
  • 资助金额:
    $ 9.71万
  • 项目类别:
A multicenter clinical trial of allopurinol to prevent GFR loss in T1D
别嘌呤醇预防 1 型糖尿病 GFR 损失的多中心临床试验
  • 批准号:
    8445008
  • 财政年份:
    2012
  • 资助金额:
    $ 9.71万
  • 项目类别:
Design of a Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
别嘌呤醇预防 1 型糖尿病 GFR 损失的多中心临床试验设计
  • 批准号:
    8250159
  • 财政年份:
    2011
  • 资助金额:
    $ 9.71万
  • 项目类别:
Analysis of the mechanisms of allopurinol-induced severe cutaneous adverse reactions
别嘌呤醇致严重皮肤不良反应的机制分析
  • 批准号:
    23790611
  • 财政年份:
    2011
  • 资助金额:
    $ 9.71万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
ALLOPURINOL AND CARDIAC FUNCTION IN IDIOPATHIC DILATED CARDIOMYOPATHY
特发性扩张型心肌病中别嘌呤醇与心脏功能
  • 批准号:
    7199117
  • 财政年份:
    2004
  • 资助金额:
    $ 9.71万
  • 项目类别:
ALLOPURINOL AND THE PREVENTION OF DEATH, TISSUE INJURY, AND SEIZURES IN CHD
别嘌呤醇与预防冠心病死亡、组织损伤和癫痫发作
  • 批准号:
    6116864
  • 财政年份:
    1998
  • 资助金额:
    $ 9.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了